- Ilaprazole
-
- $36.00
-
2026-09-02
- CAS:172152-36-2
- Min. Order: 1kg
- Purity: 99%
- Ilaprazole
-
-
2026-06-30
- CAS:172152-36-2
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1000kgs
- Ilaprazole
-
-
2026-06-30
- CAS:172152-36-2
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1000kg
|
| | Ilaprazole Basic information |
| Product Name: | Ilaprazole | | Synonyms: | 2-[(4-methoxy-3-methyl-pyridin-2-yl)methylsulfinyl]-5-pyrrol-1-yl-3H-benzoimidazole;2-[[(4-Methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-6-(1H-pyrrol-1-yl)-1H-benzimidazole;IY 81149;Ilaprazole(IY 81149);1H-BenziMidazole,2-[[(4-Methoxy-3-Methyl-2-pyridinyl)Methyl]sulfinyl]-6-(1H-pyrrol-1-yl)-;2-[(4-methoxy-3-methylpyridin-2-yl)methylsulfinyl]-6-pyrrol-1-yl-1H-benzimidazole;IY81149; IY-81149; IY 81149;Ilaprazole USP/EP/BP | | CAS: | 172152-36-2 | | MF: | C19H18N4O2S | | MW: | 366.44 | | EINECS: | 1308068-626-2 | | Product Categories: | 172152-36-2 | | Mol File: | 172152-36-2.mol |  |
| | Ilaprazole Chemical Properties |
| Boiling point | 651.0±65.0 °C(Predicted) | | density | 1.39 | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | DMF: 10mg/mL; DMSO: 15mg/mL; DMSO:PBS (pH 7.2) (1:7): 0.12mg/mL; Ethanol: 0.3mg/mL | | form | A solid | | pka | 8.23±0.10(Predicted) | | color | Off-white to gray | | InChI | InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22) | | InChIKey | HRRXCXABAPSOCP-UHFFFAOYSA-N | | SMILES | C1(S(CC2=NC=CC(OC)=C2C)=O)NC2=CC(N3C=CC=C3)=CC=C2N=1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | Ilaprazole Usage And Synthesis |
| Description | Ilaprazole is a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. A weak base, ilaprazole accumulates in the acidic environment of the secretory canaliculus of the gastric parietal cell where it is converted to an active sulfenamide form that binds to cysteine sulfhydryl groups on the luminal aspect of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production.
| | Uses | Ilaprazole is a proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. | | Definition | ChEBI: Ilaprazole is a sulfoxide and a member of benzimidazoles. | | in vivo | Ilaprazole (3-30 mg/kg; i.d.) dose-dependently inhibits gastric acid secretion[1].
In anesthetized rats, Ilaprazole dose-dependently increased gastric pH which was lowered by histamine infusion. In the case of i.v. injection, the ED50 of Ilaprazole and omeprazole is 1.2 and 1.4 mg/kg and in the case of i.d. administration, the ED50 of Ilaprazole and omeprazole is 3.9 and 4.1 mg/kg, respectively. Ilaprazole also significantly inhibits pentagastrin-stimulated gastric secretion. Its ED50 is 2.1 mg/kg and that of Omeprazole is 3.5 mg/kg with i.d. administration. In the case of i.v. injection, Ilaprazole is equipotent to Omeprazole. Ilaprazole also inhibits gastric acid secretion strongly in fistular rats. The ED50 of Ilaprazole administered intraduodenally is 0.43 mg/kg and that of Omeprazole is 0.68 mg/kg[1]. | Animal Model: | Male SD rat (after pylorus ligation)[1] | | Dosage: | 3, 10, 30 mg/kg | | Administration: | Intraduodenally | | Result: | The acid output and volume significantly inhibited by about 60 % and 46 % at 3 mg/kg were s, respectively. At 30 mg/kg, it showed 93 % and 73 % inhibition on acid output and volume, respectively.
|
|
| | Ilaprazole Preparation Products And Raw materials |
|